Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 1124 for “"ductal"”.
-
Epidemiology of ductal carcinoma in situ
… <p>Almost 7,000 people are diagnosed with ductal carcinoma in situ (DCIS) in the United Kingdom each year, but there remains uncertainty regarding its natural history and optimal management. The aim of this thesis was to evaluate factors contributing to the epidemiology of DCIS and its …
-
Imaging p53 in pancreatic ductal adenocarcinoma
<p>Pancreatic ductal adenocarcinoma (PDAC) represents 90% of pancreatic cancer cases and is characterised by poor survival rates and resistance to current therapeutic regimes as the majority of patients present with an already advanced disease at the time of diagnosis. Mutations of the …
-
FAK function in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterised by extreme stromal desmoplasia, immune evasion, and resistance to therapy. Focal Adhesion Kinase (FAK) is a central transducer that integrates signals from the extracellular matrix and growth factors, …
-
Cell of origin in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a ductal morphology. Prior research has identified both pancreatic acinar and ductal cells as possible cells of origin for histologically similar PDAC. However, because different mutations were induced in acinar and ductal cells, apt …
-
T CELL TRAFFICKING IN PANCREATIC DUCTAL ADENOCARCINOMA
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies with a five-year survival rate of less than 10%. A key challenge in PDAC treatment is its immunologically “cold” tumor microenvironment, characterized by a paucity of infiltrating T cells and a dominance of …
-
Regulation of CYP3A5 in Pancreatic Ductal Adenocarcinoma
… amounts in some cancers, including pancreatic ductal adenocarcinoma (PDAC). There have been several published studies regarding CYP3A5 regulators, but there is still much to be discovered concerning CYP3A5 regulation in cancer. To further understand the regulation of CYP3A5, a high-throughput …
-
T Cell Immunosurveillance in Pancreatic Ductal Adenocarcinoma
ABSTRACT T CELL IMMUNOSURVEILLANCE IN PANCREATIC DUCTAL ADENOCARCINOMA Rebecca A. Evans Robert H. Vonderheide The prevailing theory of cancer immune surveillance, as understood from carcinogen-driven mouse models of highly mutated tumors, states that T cell-mediated immune pressure drives a …
-
Tyrosine kinase signalling in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) has the most dismal prognosis of all solid tumours and an overall 5-year survival rate of < 5%, a statistic that has not changed in almost 50 years (Jemal et al., 2009). This is a reflection of the late presentation of PDAC patients to the clinic, and the …
-
Novel Targets And Therapeutics in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis of all major malignancies. As there is no effective treatment method, it is emerging as one of the most deadly cancers. Oncogenic activation of KRAS is the most commonly seen mutation with 95% frequency in PDAC. Inhibition or …
-
Therapeutic Potential of Piperlongumine for Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies because it is often diagnosed at a late disease stage and has a poor response rate to currently available treatments. Therefore, it is critical to develop new therapeutic approaches that will enhance the efficacy and …
-
Prognostic molecular markers in resected ductal pancreatic carcinoma
… fixed, paraffin-embedded specimens of pancreatic ductal adenocarcinoma were analysed from 157 patients (100 men and 57 women with a median [range] age of 60 [33-77] years) who had undergone pancreatectomy. Immunhistochemistry was used to detect expression of p16\(^{INK4}\), p53, p21\(^{WAF1}\), …
-
Imaging ductal carcinoma using a hyperspectral imaging system
… from each patient included both normal and ductal carcinoma tissue, both stained and unstained. These cells were imaged using a snapshot HSI system, and the spectral reflectances were evaluated to see if there was a measurable spectral difference between the various cell types. Analysis of …
-
RET-receptor mediated invasion in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is frequently associated with invasion along nerves, which generates severe pain. KRAS and TP53 are the most common driving mutations for PDAC, however, these tumours also overexpress the RET receptor which regulates cell proliferation and migration. Since …
-
The functional role of MAP3K2 in pancreatic ductal adenocarcinoma
… oncogenic role of MAP3K2 in pancreatic ductal adenocarcinoma (PDAC), a malignant tumor typically associated with a very poor prognosis. This study aimed to investigate the functional relevance of MAP3K2 in PDAC by combining RNA interference-based gene silencing in vitro with …
-
EPAC1 AS A THERAPEUTIC TARGET FOR PANCREATIC DUCTAL ADENOCARCINOMA
… promoting invasion and metastasis of pancreatic ductal adenocarcinoma (PDA) and immune regulation, through modulation of the activity of regulatory T-cells (Treg), a subset of T-cells that suppress the immune system and maintain immune tolerance. In three common PDA cell lines, AsPC-1, PANC-1, …
-
Developing Novel and Effective Treatments for Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with a 5-year survival rate of 8%. Over 80% of patients are diagnosed with locally advanced or metastatic disease and undergo systemic chemotherapy with gemcitabine. Virtually all patients develop gemcitabine-resistant disease and …
Page 1 of 57